Streetbeat News

Stock Prices

AAPL

AMZN

META

MSFT

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo discusses trade strategies for SPY, QQQ, AAPL, MSFT, META, TSLA, and AMZN. The memo provides detailed analysis of each stock, including potential bullish and bearish scenarios. The analysis is based on a proprietary formula that takes into account price, volume, and options flow. The memo advises traders to monitor these stocks closely and be prepared to leverage potential breakouts or reversals.

Portfolio Pulse from RIPS

September 22, 2023 | 2:27 pm

FAMI

Farmmi, Inc. (NASDAQ:FAMI) announced that its shareholders have approved a one-for-eight share consolidation. The move aims to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its Nasdaq listing. The consolidation will reduce the number of ordinary shares from 47,470,672 to approximately 5,933,834. The consolidation will be effective from September 25, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 2:23 pm

AVTX

CCG

FLJ

MLGO

NEPT

PBTS

US stocks traded slightly higher with the Nasdaq Composite gaining around 50 points. The S&P Global manufacturing PMI rose to 48.9 in September from 47.9 in the prior month, beating market estimates of 48. MicroAlgo Inc. (NASDAQ:MLGO), Cheche Group Inc. (NASDAQ:CCG), and Avalo Therapeutics, Inc. (NASDAQ:AVTX) saw significant gains, while Neptune Wellness Solutions Inc. (NASDAQ:NEPT), Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS), and FLJ Group Limited (NASDAQ:FLJ) experienced drops.

Portfolio Pulse from Lisa Levin

September 22, 2023 | 2:22 pm

SDS

SQQQ

SRTY

The stock market has been falling recently due to rising interest rates, a strong dollar, and concerns about a potential recession. This has affected all sectors, with technology stocks being particularly hard hit. However, this also presents opportunities for traders to profit through strategies such as short selling, buying inverse ETFs like ProShares UltraShort S&P500 ETF (SDS), ProShares UltraShort QQQ ETF (SQQQ), and ProShares UltraShort Russell 2000 ETF (SRTY), and using put options.

Portfolio Pulse from Sandra Stone

September 22, 2023 | 2:21 pm

ESALF

ESALY

MRK

Merck & Co Inc and Eisai Co Ltd have announced that two Phase 3 trials, LEAP-006 and LEAP-008, evaluating Keytuda plus Lenvima in patients with certain types of metastatic non-small cell lung cancer, did not meet their primary endpoints. The safety profiles of the treatment regimens were consistent with previous studies. Keytruda plus Lenvima is approved in the U.S., the EU, Japan, and other countries for advanced renal cell carcinoma and certain types of advanced endometrial carcinoma.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 2:21 pm

TGT

Target Corp's (TGT) shares are trading lower by 2.4% to $114.48, hitting a new 52-week low. The drop is attributed to concerns about future rate hikes following the recent FOMC statement and lower-than-expected initial jobless claims data. Higher interest rates could lead to higher borrowing costs for consumers, potentially reducing consumer spending at retailers like Target.

Portfolio Pulse from Henry Khederian

September 22, 2023 | 2:21 pm

XPEV

XPeng Inc. (NYSE:XPEV) shares are trading higher due to renewed interest in Chinese stocks amid hopes for improving growth. This comes as Chinese regulators loosen restrictions on foreign capital movement to attract foreign investors and aid economic recovery. Despite the rise, XPEV's stock is still down 8% over the last five days.

Portfolio Pulse from Erica Kollmann

September 22, 2023 | 2:20 pm

FEAM

5E Advanced Materials announced that it has received authorization from the Environmental Protection Agency to conduct Step-Rate Testing under its existing permit. This news has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 2:20 pm

NEPT

Neptune Wellness Solutions Inc (NASDAQ:NEPT) announced a $4.5 million public offering of 1.8 million shares at $2.50 per share, causing its shares to drop by 45% to $2.20. The company plans to use the proceeds for working capital, including payment of accounts payable due to suppliers. The closing of the offering is expected on September 26.

Portfolio Pulse from Henry Khederian

September 22, 2023 | 2:18 pm

BMY

Bristol Myers Squibb & Co (NYSE:BMY) announced that its lead cancer drug, Opdivo, met its primary goal in a Phase 3 lung cancer study. The trial showed a significant improvement in event-free survival (EFS) compared to neoadjuvant chemotherapy and placebo. The company plans to share the results at an upcoming medical conference and discuss with health authorities.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 2:18 pm